Wird geladen...
A Phase II Study of Two Dose Levels of Ofatumumab Induction followed by Maintenance Therapy in Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Despite the recent advances in treatment of CLL with targeted agents such as ibrutinib, availability of non-chemotherapy based therapies is desired. Given the 58% response rate (1996 NCI-WG criteria) of single agent ofatumumab in CLL refractory to fludarabine and alemtuzumab, we initiated a phase II...
Gespeichert in:
| Veröffentlicht in: | Am J Hematol |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5500306/ https://ncbi.nlm.nih.gov/pubmed/27387131 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24468 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|